Dopaminergic agents and nutritional status in Parkinson's disease

Movement Disorders

Volumn 29, Issue 12, 2014, Pages 1543-1547

  Laudisio, Alice ^a   Vetrano, Davide L ^b   Meloni, Eleonora ^b   Ricciardi, Diego ^b   Franceschi, Francesco ^b   Bentivoglio, Anna Rita ^b   Bernabei, Roberto ^b   Zuccalà, Giuseppe ^b  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Dopaminergic drugs; Epidemiology; Levodopa; Nutritional status; Parkinson's disease

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DIHYDROERGOCRYPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LISURIDE; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE;

AGED; ARTICLE; DRUG USE; FEMALE; GERIATRIC HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; MINI NUTRITIONAL ASSESSMENT; NUTRITIONAL ASSESSMENT; NUTRITIONAL STATUS; PARKINSON DISEASE; PRIORITY JOURNAL; TREND STUDY; CHEMICALLY INDUCED; DRUG EFFECTS; MIDDLE AGED; PHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DOPAMINE AGENTS; FEMALE; HUMANS; LEVODOPA; MALE; MALNUTRITION; MIDDLE AGED; NUTRITIONAL STATUS; PARKINSON DISEASE;

EID: 84927517222     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25991     Document Type: Article

References (26)

1. Sheard JM, Ash S, Silburn PA, Kerr GK. Prevalence of malnutrition in Parkinson's disease: a systematic review. Nutr Rev 2011;69:520-532.
2. Barichella M, Cereda E, Pezzoli G. Major nutritional issues in the management of Parkinson's disease. Mov Disord 2009;24:1881-1892.
3. Jaafar AF, Gray WK, Porter B, Turnbull EJ, Walker RW. A cross-sectional study of the nutritional status of community-dwelling people with idiopathic Parkinson's disease. BMC Neurol 2010;10:124.
4. Pålhagen S, Lorefält B, Carlsson M, Ganowiak W, Toss G, Unosson M, Granérus AK. Does L-dopa treatment contribute to reduction in body weight in elderly patients with Parkinson's disease? Acta Neurol Scand 2005;111:12-20.
5. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
6. Guigoz Y, Vellas B, Garry PJ. Assessing the nutritional status of the elderly: The Mini Nutritional Assessment as part of the geriatric evaluation. Nutr Rev 1996;54:S59-S65.
7. Oertel Wh, Schulz J. Parkinson syndrome. In: Brandt T, Dichgans J, Diener HC, Therapie und Verlauf neurologischer Erkrankungen. Stuttgart: Kohlhammer-Verlag, 2003:847-880.
8. Ferraroni M, Decarli A, Franceschi S, et al. Validity and reproducibility of alcohol consumption in Italy. Int J Epidemiol 1996;25:775-782.
9. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged: the index of ADL: a standardized measure of biological and psychosocial function. JAMA 1963;185:414-419.
10. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982-1983;17:37-49.
11. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
12. Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 2003;18:738-750.
13. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Methodology: History.
14. [cited 2012 June 26]. Available from: http://www.who.int/classifications/icd/en/.
15. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383.
16. Laudisio A, Marzetti E, Antonica L, et al. Masticatory dysfunction is associated with osteoporosis in older men. J Clin Periodontol 2007;34:964-968.
17. Nakayama Y, Washio M, Mori M. Oral health conditions in patients with Parkinson's disease. J Epidemiol 2004;14:143-150.
18. Marczewska A, De Notaris R, Sieri S, Barichella M, Fusconi E, Pezzoli G. Protein intake in Parkinsonian patients using the EPIC food frequency questionnaire. Mov Disord 2006;21:1229-1231.
19. Adams F, Boschmann M, Lobsien E, et al. Influences of levodopa on adipose tissue and skeletal muscle metabolism in patients with idiopathic Parkinson's disease. Eur J Clin Pharmacol 2008;64:863-870.
20. Gibson CD, Karmally W, McMahon DJ, Wardlaw SL, Korner J. Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults. Diabetes Obes Metabol 2012;14:335-340.
21. Reis FM, Reis AM, Coimbra CC. Effects of hyperprolactinaemia on glucose tolerance and insulin release in male and female rats. J Endocrinol 1997;153:423-428.
22. Cooper SJ, Al-Naser HA, Clifton PG. The anorectic effect of the selective dopamine D1-receptor agonist A-determined by meal pattern analysis in free-feeding rats. Eur J Pharmacol 2006;532:253-257.
23. Cáceres-Redondo MT, Carrillo F, Lama MJ, et al. Long-term levodopa/carbidopa intestinal gel in advanced Parkinson's disease. J Neurol 2014;261:561-569.
24. Kumru H, Santamaria J, Valldeoriola F, Marti MJ, Tolosa E. Increase in body weight after pramipexole treatment in Parkinson's disease. Mov Disord 2006;21:1972-1974.
25. Raja M, Bentivoglio AR. Impulsive and compulsive behaviors during dopamine replacement treatment in Parkinson's Disease and other disorders. Curr Drug Saf 2012;7:63-75.
26. Barone P, Scarzella L, Marconi R, et al. Depression/Parkinson Italian Study Group. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J Neurol 2006;253:601-607.